In 1958, Raben extracted growth hormone (GH) from human pituitary glands at post mortem, I and used intramuscular injections for a period of 10 months to produce an increased growth rate in a 17-year-old male with hypopituitarism.? By 1976, 642 children with growth hormone deficiency had been treated with human pituitary GH in the UK;~and in early 1985 around 900 children in the UK were receiving GH therapy." During that year, there were reports of four deaths from the rare encephalopathy, Creutzfeldt-Jakob disease, in young adults who had been treated with GH. 5 -7 Although it seems that pituitary glands extracted by current methods do not contain the virus responsible for Creutzfeldt-Jakob disease," treatment with human pituitary GH has been stopped in most countries. However, in the early I 98(ls, it became possible to synthesise the biologically-active methionyl analogue of human GH by recombinant DNA technology:' and results of a successful clinical trial in 36 children with GH deficiency have been reported. HI Thus, it seems likely that supplies of GH for therapeutic use, previously scarce, will become abundant in the near future. The time is ripe for a reappraisal of who is likely to benefit from GH therapy.
Diagnostic methods
Investigation of a child suspected of having GH deficiency can be conveniently divided into four modes of approach: the assessment of general health, detailed anthropometry and bone age assessment, biochemical testing and investigations of possible causes of proven GH deficiency.
ASSESSMENT OF GENERAL HEALTH
A thorough clinical assessment backed up by A previous version of this review is to be published in Physician India. We thank the Editor for permission to republish. Correspondence: Dr I Gunn, Biochemistry Department, Law Hospital. Carluke, Lanarkshire, UK. some simple biochemical and radiological investigations will point towards the cause of short stature in some patients. There are a number of acquired diseases. such as defects of nutrition, digestion or absorption, chronic infections, hypothyroidism, social and emotional deprivation, in which treatment of the primary condition will result in the restoration of normal growth and so treatment with GH need not be considered.
In inherited disorders associated with small stature, but apparently normal GH output from the pituitary, the place of GH therapy is controversial. For example. although early reports indicated that children with achondroplasia and Turner's syndrome do not respond." II cases of an increased height velocity in Turner's syndrome have been reported.P: 13
ANTHROPOMETRY AND BONE AGE
Methods of anthropometric assessment have been well described." As far as possible all measurements on one patient should be made by the same person(s) using the same equipent. Until the age of 3 years. supine length is measured by lying the child on a flat surface on his back. One observer holds the head in contact with a board at the top end. of the surface. while another straightens the legs. turns the feet upwards at right angles to the legs. and brings a sliding board into contact with the child's heels. From the age of 2 onwards, standing height is taken without shoes, the child standing with his heels and back in contact with a vertical wall. The head is held so that he looks straight forward, and a rightangled block is slid down the wall until its lower surface touches the child's head. The height is read off a scale fixed to the wall. Measurements should be made to the nearest (l·1 em. The precision of the measurements will be further improved if they are made in a centre with experience of the techniques. In the UK, there are around 20 regional centres approved for 429 making such measurements. 15 The supine length or standing height is measured every 3 months and the result plotted on charts containing information on the ranges of height and growth velocity in normal children according to age and sex. The range of normal growth is usually expressed in terms of either 'centiles', or standard deviations (SD) from the mean of that age group. For example, a child with a height on the 3rd centile will be approximately 2 SD below the mean.
Most methods for estimating bone age depend on the radiological appearances of the bones of the wrist and hand. \1> The degree of accuracy again depends upon the use of age-and sex-based reference standards, and is increased if the same observer interprets serial measurements.
Careful evaluation of the information gained over a period of 1 year, perhaps taking into account the height of the child's parents.!? allows an accurate prediction of the final adult height of the child. III The recent practice of most paediatric endocrinologists has been, that if the growth velocity is above the 25th centile, and the predicted adult height is adequate, then the child's parents may be reassured that no therapeutic intervention is required. The majority of children being investigated for GH deficiency in a growth clinic will have this outcome, and it is not known whether administration of GH in the doses currently used for the treatment of GH deficiency will result in a further increase in adult height.
In contrast, there are children who have no obvious clinical cause for their short stature, but are growing slowly, and have a low predicted adult height and, usually, a retarded bone age. The next step in the investigation of such children is normally that of biochemical testing.
BIOCHEMICAL TESTING
Since it has been possible to measure the concentration of plasma GH, usually by radioimmunoassay, a great deal of effort has been expended in the pursuit of the ideal biochemical test to diagose GH deficiency. the dilemma is that plasma GH concentration in the basal state is normally low, and so some form of stimulus is required to show that the somatotrope cells of the pituitary can release adequate amounts of GH into the circulation. Two types of stimuli may be used-physiological and pharmacological. Exercise and sleep are the two commonly used physiological stimuli. It has been possible to standardise the exercise test and adapt its use for very young children, using fairly simple apparatus, I'!. 211 and this approach has apparently allowed some growth centres to exclude the diagnosis of GH deficiency by use of a single blood sample without resorting to more complicated procedures.
Random blood sampling during sleep may be a useful method for excluding GH deficiency." but since secretion of GH is associated with stage IV (slow-wave) sleep. samples taken under electroencephalographic control are needed to improve the test such that its specificity is comparable with that of pharmacological stimuli. 22 In the UK up until 1985, treatment with GH was not considered until it had been shown that the child could not respond adequately to a pharmacological stimulus of GH secretion. For many years insulin-induced hypoglycaemia was the stimulus of choice," even allowing for its unpleasant side-effects and requirement for serial blood sampling and close monitoring of the patient.
Oral administration of the hypotensive agent clonidine has been shown to stimulate GH secretion.P and the test is more pleasant for the patient, easier to perform. and at least as diagnostically useful as the insulin-induced hypoglycaemia test. 24 • 25 A third commonly used pharmacological stimulus is intravenous infusion of the amino acid arginine.F" 27 The sequential use of arginine infusion and insulin-induced hypoglycaemia on the same day is preferred by some centres.P" 2 '1 Controversy has surrounded the choice and interpretation of these stimulation tests. No matter which two tests are compared in population studies, some discrepant results appear. Studies which have followed up a sufficient number of discrepant results in a controlled manner with assessment of response to GH therapy have been few. The approach of the Health Services Human Growth Hormone Committee (HSHGHC) of the UK has been to employ the physiological tests as a screen to exclude GH deficiency by attempting to show a plasma GH level of at least 15 mUlL (7,5 ugIL). If this value is not reached, a pharmacological stimulus is then used. Again, peak values above 15 mUlL are taken to exclude GH deficiency, although many centres outside the UK use 20 mUlL (10 ug/L) as the value for this purpose. A peak level below 7 mUlL confirms the diagnosis of GH deficiency. Peak values between 7 and (different) pharmacological stimulus. If the value falls below 15 mUlL on this second occasion. the child is then referred for Gil therapy. If the child has a bone age greater than to years. this series of tests and interpretation takes place after sex hormone priming. IS There are several problems with this approach. Firstly. the radioimmunoassays and immunoradiometric assays for GH are imprecise. Participants in the UK External Quality Assessment Scheme report interbatch coefficients of variation between 4 and 16'}Io (I Hanning. personal communication). At an average CY of )()%. the 95'1., range of measured values at the levels of 7 mUlL and 15 mUlL will be 5·6-8·4 mUlL and 12-18 ml.J/L, respectively. Secondly. a minority of children who have a poor response to pharmacological stimuli subsequently grow well without therapeutic intervention ..1()· 311 Perhaps more importantly. however. evidence is accumulating that many short children who arc growing slowly. but have a normal Gil response to pharmacological stimuli. will respond to administration of standard doses of G H replacement thera~y with a significant increase in growth vclocity.f" 31 36 The proportion who respond has varied from 40 to 100%. and the effect has been shown to be sustained for at least I year. 35 Thus. it appears that many more children than previously thought may benefit from GH treatment. and that while stimulation tests may be useful to confirm severe G H deficiency. they may be too insensitive to detect lesser. but significant. problems. Is it. then. possible to predict which short. slowly growing children will respond to GH therapy'? There are a number of more recently introduced biochemical investigations which have shown promise in this respect.
One possibility is that the children who appear to have a normal response to stimulation tests are secreting a Gil molecule which is immunologically detectable by radioimmunoassay techniques. but is biologically inactive. Use of a radioreceptor assay37 may reveal the low levels of bioactive GH. However. it has been recently reported that normal growth may occur in the presence of low levels of GH measured by both radioimmunoassay and radioreceptor assay.311
Measurement of somatomedin-C (insulinlike growth factor I) in the plasma and the increase in levels in response to a IO-day course of large doses of GH has been profferred as a
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good predictor of subsequent response to therapy." This has been challenged by subsequent reports.F: 3.1 but a greater degree of separation of normal from abnormal values by taking the mean of four samples at 6-weekly intervals can be achieved." Using this method. 44 slowly growing children with low somatomedin-C levels. some of whom had normal GH levels on stimulation testing. all responded to a 6-month course of GH therapy with an increased growth velocity. There are. however. a number of factors which alter plasma somatomedin-C levels. including age and nutritional status. and comparison of results from different laboratories is currently of doubtful significance due to problems in standardisation of individual assay systems . . 19 Twenty-four-hour secretion of Gil may be assessed by inserting an indwelling venous catheter and taking samples every 20 min to examine the number and height of pulses of GH release.F' Alternatively. samples can be withdrawn continuously into a container which is changed every 30 min. and aliquots of the plasma from each container pooled. This latter approach has been referred to as the 24 h integrated concentration of G H. 4 (1 It has the advantage of requiring one measurement of G H instead of 72. A study of pulsatile secretion of GH in short and normal children has suggested that there is a spectrum of GH secretory abnormalities from absolute Gil deficiency to an intermittent irregularity in secretion, and that children with 'neurosecretory dysfunction' respond well to GH replacement therapy..15 A study of 24 h integrated concentration of GH has supported the idea of a continuous spectrum of GH secretion,"! but the relationship between 24 h integrated GH concentration and response to treatment has not yet been shown.
One final avenue of approach is to consider that some cases of GH deficiency are due to hypothalamic damage, and that stimulation of pituitary GH secretion by GH releasing factor may yield a result that is different to that obtained with other pharmacological stimulj, 42 To summarise. in contrast to assessment of height. growth velocity and bone age, biochemical tests for the diagnosis of GH deficiency are unpleasant for the patient, expensive and imprecise. There is no convincing evidence that anyone test. or combination of tests, is better at predicting a response to GH treatment than anthropometric measurements. Their main role in the past has been to diagnose severe GH deficiency in order to select patients who would benefit most from the limited supplies of GH.
INVESTIGATION OF CAUSES OF Gil DEFICIENCY
GH deficiency may be either acquired or idiopathic, the latter having a significant genetic component.Y'<" The cause of acquired GH deficiency may be clinically obvious. Reduced GH secretion has been shown in children who survived cranial irradiation and intrathecal chemotherapy for acute lymphoblastic leukaemia.r' and treatment with GH has been shown to increase the growth velocity of nine children who received cranial irradiation for various malignancies and subsequently experienced decreased growth velocity." Other acquired cases of GH deficiency may require intensive neuroradiological investigation before the cause is discovered. A summary of the techniques is given by Kendall." The idiopathic form of the disease may be divided into isolated OH deficiency and multiple pituitary hormone deficiency. Multiple hormone deficiency may be diagnosed by formal stimulation tests of anterior pituitary function, such as the thyrotrophin-releasing hormone (TRH) test, luteinising hormone-releasing hormone (LH-RH) test and insulin-induced hypoglycaemia. A few authors have suggested that around 50% of cases of idiopathic GH deficiency are associated with decreased secretion of other pituitary hormones, but if one is prepared to accept that lesser degrees of isolated GH deficiency exist, the number of cases of isolated deficiency will increase, and the prevalence of other hormone deficiencies may be as low as ll~o;'): 1 The number of cases of idiopathic GIl deficiency that are seen will depend upon the population under study, and the energy with which the diagnosis is pursued. By recording cases, diagnosed by a poor response of 0 II secretion to hypoglycaemia, and treated in a clinic in Newcastle, and comparing their numbers with the birth rate for that region, Parkin 4l > estimated the incidence to be one in 30 O(J() births. Active screening of the heirhts of 48 221 children in three Scottish cities," followed by formal stimulation testing of Gil secretion, suggested that the prevalence is likely to be around one per )() ()()() 6-9-year-old children, and possibly as high as one in 40()().
A review of world literature suggests that the sex ratio is 2·9 boys to one girl. 43 However, when cases were actively sought in the community, the ratio was much closer, suggesting that patterns of referral may account for the reported differences." Treatment Since Raben's original rcport.i the tendency has been to inject GH by the intramuscular route two to three times per week. It has been estimated that a twice weekly dose of J() IU (20 mg) would produce a height increase J() ern greater that that produced hy twice weekly 5 IU over a Hl-year period in CHI-deficient children." However, in the short term at least. growth velocity has been shown to he greater still using 5 IV three times per week, which is the regime which has been adopted in the UK: 1 Treatment is continued until growth ceases. In the US, dosage is adjusted according to the child's weight, the usual dose being (J·I IUlkg intramuscularly three times per week.
However, it has heen shown that subcutaneous injections are just as effective as intramuscular, and more acceptable to the patient's family." In Sweden, daily administration of 011 subcutaneously was compared with the same total weekly dose given hy the standard three times per week intramuscular routc.:" Over the first year of therapy, the growth rate increased in all children on daily subcutaneous treatment. The increased velocitv was not sustained into the second year. hut an increased predicted final height was found. The regime was extremely well tolerated hy the children and their parents with no adverse effects.
In many countries, the supply and distribution of pituitary Gil was controlled hy a centralised hody such as the Health Services Human Growth Hormone Committee of the UK. With the advent of synthetic methionyl Gil, a new prohlem has arisen-who should he permitted to prescrihe this drug'! Methionyl Gil is of similar potency to pituitary Gil. and a vial containing 4 IU costs £28. Thus, a year's therapy will cost, on average, more than £40()(). In the UK, the data sheet for Somatonorrn'" states that it may be used for the treatment of short stature caused hy decreased or absent secretion of pituitary GH, and that the diagnosis should he verified hy appropriate investigations of pituitary function hy a 'specialist medical practitioner'. In practice, this probably means that a general practitioner may take over prescription of therapy which has been commenced by a paediatric endocrinologist.
The future
We stand on the threshold of a revolution in growth hormone therapy. The small amount of information available to us suggests that the majority of slowly growing short children who can respond to pharmacological stimulation by secretion of Gil will nevertheless respond. at least in the short term. to GH treatment by increasing growth velocity. Currently. there is no way we can accurately predict which children will respond. Perhaps the greatest hope for the future lies in molecular analysis of idiopathic disorders by modern genetic techniques.S! In the meantime. a therapeutic trial of GH may be the only way to satisfy demands for treatment. If such a trial is undertaken. it is essential that patients are carefully evaluated in order to exclude other treatable causes of short stature. and that therapy is evaluated by comparison of precise measurements of growth rate for at least 6 months before and after therapy. Unfortunately. it seems unlikely that such trials will now include placebo therapy. Such a trial organised in the UK had to be abandoned in 1985 due to the reports of Creutzfeldt-Jakob disease in patients treated with pituitary G H.:l-7 The incomplete results suggested that the treatment group had grown faster than the placebo group. but the results were not statistically significant.13 Other factors should be taken into consideration when embarking on such a trial. The effect of therapy on the final height of children who can respond to pharmacological stimulation is not known. Likewise. we are ignorant of the ultimate physical and psychological benefits and side-effects. What we do know is the extent of the financial burden. which would be considerable.
Finally. prepubertal pituitary tumours which secrete GH cause gigantism. Therefore. it may be tempting to attempt to increase the height of normal children by administration of large doses of GH. In addition to the danger that such treatment will result in medical complications. such as diabetes mellitus and cardiovascular atheroma. further philosophical and medical issues are raised. While it seems desirable to prevent the avoidable occurrence of a group of Lilliputians. it is quite another matter to stimulate the existence of a population of Brobdignagians.S3
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